EA202092006A1 - CD83-BINDING CHIMERIC ANTIGENIC RECEPTORS - Google Patents
CD83-BINDING CHIMERIC ANTIGENIC RECEPTORSInfo
- Publication number
- EA202092006A1 EA202092006A1 EA202092006A EA202092006A EA202092006A1 EA 202092006 A1 EA202092006 A1 EA 202092006A1 EA 202092006 A EA202092006 A EA 202092006A EA 202092006 A EA202092006 A EA 202092006A EA 202092006 A1 EA202092006 A1 EA 202092006A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disclosed
- cells
- donor cells
- express
- cars
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Раскрыты композиции и способы предупреждения болезни "трансплантат против хозяина" (GVHD) у субъектов, получающих донорские клетки. В частности, раскрыты полипептиды химерного антигенного рецептора (CAR), которые можно использовать совместно с адоптивным переносом клеток для подавления аллореактивных донорских клеток. Также раскрыты иммунные эффекторные клетки, такие как Т-клетки или естественные клетки-киллеры (NK), которые сконструированы с обеспечением экспрессии таких CAR. Соответственно, также раскрыты способы подавления аллореактивных донорских клеток у субъекта, получающего донорские клетки при трансплантации, которые предусматривают адоптивный перенос раскрытых иммунных эффекторных клеток, сконструированных с обеспечением экспрессии раскрытых CAR.Compositions and methods of preventing graft versus host disease (GVHD) in subjects receiving donor cells are disclosed. In particular, chimeric antigen receptor (CAR) polypeptides are disclosed that can be used in conjunction with adoptive cell transfer to suppress alloreactive donor cells. Also disclosed are immune effector cells, such as T cells or natural killer (NK) cells, that are engineered to express such CARs. Accordingly, methods of inhibition of alloreactive donor cells in a subject receiving donor cells by transplant are also disclosed, which involve adoptive transfer of disclosed immune effector cells engineered to express disclosed CARs.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862677783P | 2018-05-30 | 2018-05-30 | |
PCT/US2019/019065 WO2019165156A1 (en) | 2018-02-23 | 2019-02-22 | Cd83-binding chimeric antigen receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202092006A1 true EA202092006A1 (en) | 2020-11-20 |
Family
ID=73649849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202092006A EA202092006A1 (en) | 2018-05-30 | 2019-02-22 | CD83-BINDING CHIMERIC ANTIGENIC RECEPTORS |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA202092006A1 (en) |
-
2019
- 2019-02-22 EA EA202092006A patent/EA202092006A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020500632A1 (en) | Cd83-binding chimerix antigen receptors | |
MX2021005022A (en) | Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d). | |
PH12020552138A1 (en) | Bcma chimeric antigen receptors and uses thereof | |
MX2020010241A (en) | Cellular immunotherapy compositions and uses thereof. | |
EA201992469A1 (en) | ANTIGEN SPECIFIC IMMUNE EFFECTIVE CELLS | |
EA201790624A1 (en) | AIMING OF CYTOTOXIC CELLS WITH CHEMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY | |
MX2021009087A (en) | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1). | |
WO2017011804A8 (en) | Engineered cells for adoptive cell therapy | |
WO2016011210A3 (en) | Engineered cells for adoptive cell therapy | |
AR110676A1 (en) | TREATMENT OF CANCER USING CHEMERIC ANTIGENS RECEPTORS | |
EA202092945A1 (en) | DIFFERENT ANTIGEN BINDING DOMAINS, NEW PLATFORMS AND OTHER IMPROVEMENTS FOR CELL THERAPY | |
PH12020551671A1 (en) | Chimeric receptors to dll3 and methods of use thereof | |
EA202091982A1 (en) | Chimeric antigenic receptor to the receptor of IL-13 ALPHA 2 (IL13R2) for tumor-specific T-cell immunotherapy | |
MX2020010235A (en) | Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof. | |
MX2017005344A (en) | Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy. | |
MX2019014008A (en) | Compositions and methods for immunotherapy. | |
JP2018524987A5 (en) | ||
MX370173B (en) | Cs1-specific chimeric antigen receptor engineered immune effector cells. | |
MX2022015062A (en) | Novel constructs for chimeric antigen receptors. | |
MX2020007281A (en) | Compositions and methods for targeting cd99-expressing cancers. | |
MX2020007338A (en) | Compositions and methods for targeting clec12a-expressing cancers. | |
MX2019015484A (en) | Chimeric antigen receptors with mutated cd28 costimulatory domains. | |
MX2020007357A (en) | Pd1-specific chimeric antigen receptor as an immunotherapy. | |
CR20210091A (en) | Chimeric receptors to steap1 and methods of use thereof | |
ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof |